CRBU FY2029 EPS Reduced by Brookline Capital Management

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities researchers at Brookline Capital Management dropped their FY2029 earnings per share estimates for shares of Caribou Biosciences in a research report issued to clients and investors on Tuesday, March 11th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings of $16.83 per share for the year, down from their prior estimate of $16.92. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The business had revenue of $2.08 million during the quarter, compared to the consensus estimate of $2.11 million.

CRBU has been the subject of a number of other reports. Citigroup reduced their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 26th. Bank of America decreased their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a research report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Caribou Biosciences presently has an average rating of “Buy” and an average price target of $10.33.

Caribou Biosciences Price Performance

NASDAQ CRBU opened at $1.06 on Wednesday. The company has a fifty day moving average price of $1.40 and a 200-day moving average price of $1.79. The firm has a market cap of $95.99 million, a price-to-earnings ratio of -0.64 and a beta of 2.34. Caribou Biosciences has a 1 year low of $1.01 and a 1 year high of $5.94.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Intech Investment Management LLC purchased a new stake in Caribou Biosciences during the third quarter valued at about $43,000. Charles Schwab Investment Management Inc. raised its position in shares of Caribou Biosciences by 19.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company’s stock valued at $1,449,000 after purchasing an additional 118,325 shares during the period. FMR LLC lifted its stake in shares of Caribou Biosciences by 7.4% during the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock valued at $3,100,000 after buying an additional 109,606 shares in the last quarter. Walleye Capital LLC boosted its holdings in Caribou Biosciences by 45.9% in the 3rd quarter. Walleye Capital LLC now owns 237,599 shares of the company’s stock worth $466,000 after buying an additional 74,799 shares during the period. Finally, PFM Health Sciences LP grew its stake in Caribou Biosciences by 5.5% in the 3rd quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after buying an additional 223,299 shares in the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.